Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma
Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma
复制标题
DOI：
10.1097/mpa.0b013e3182021376
复制
发表时间：
2011-04-01
期刊：
影响因子：
2.9
通讯作者：
Mitsunaga, Shuichi
中科院分区：
文献类型：
--
作者：
Morizane, Chigusa;Okusaka, Takuji;Mitsunaga, Shuichi
目的：探讨影响转移性胰腺腺癌患者预后的因素。方法：通过对409例连续接受吉西他滨方案治疗的转移性胰腺腺癌患者的数据进行多因素回归分析，研究患者特征与预后之间的关系，并根据患者预后不良的预后因素数量将患者分为3个危险组。对145名接受吉西他滨以外药物治疗的患者的验证数据集进行了分析。对每例患者应用预后指标。结果：多因素回归分析显示，疼痛、腹膜播散、肝转移和血清c反应蛋白升高是缩短生存时间的重要因素。根据患者危险因素的数量将患者分为3组，3组患者的预后有显著差异。当将预后指标应用于验证数据集时，发现3组患者各自的预后存在显著差异。结论：疼痛、腹膜播散、肝转移和血清c反应蛋白升高是转移性胰腺腺癌患者预后的重要因素。
Objectives: To identify prognostic factors in patients with metastatic pancreatic adenocarcinoma.Methods: The relationship between patient characteristics and outcome was examined by multivariate regression analyses of data from 409 consecutive patients with metastatic pancreatic adenocarcinoma who had been treated with a gemcitabine-containing regimen, and we stratified the patients into 3 risk groups according to the number of prognostic factors they had for a poor outcome. A validation data set obtained from 145 patients who had been treated with agents other than gemcitabine was analyzed. The prognostic index was applied the each of the patients.Results: The multivariate regression analyses revealed that the presence of pain, peritoneal dissemination, liver metastasis, and an elevated serum C-reactive protein value significantly contributed to a shorter survival time. The patients were stratified into 3 groups according to their number of risk factors, and their outcomes of the 3 groups were significantly different. When the prognostic index was applied to the validation data set, the respective outcomes of the 3 groups were found to be significantly differed from each other.Conclusions: Pain, peritoneal dissemination, liver metastasis, and an elevated serum C-reactive protein value are important prognostic factors for patients with metastatic pancreatic adenocarcinoma.